Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model plasmodium vinckei

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  LaCrue, Alexis N ^a   Scheel, Misty ^a   Kennedy, Katherine ^a   Kumar, Nikesh ^a   Kyle, Dennis E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; MALARIA; MONOTHERAPY; MORPHOLOGY; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PARASITE RECRUDESCENCE; PARASITE SURVIVAL; PLASMODIUM PETTERI; PLASMODIUM VINCKEI; RECURRENT INFECTION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STRAIN DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECT; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM;

ARTESUNATE; MUS; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; RODENTIA; VERTEBRATA;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; MALARIA; MICE; PLASMODIUM;

EID: 80055027373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026689     Document Type: Article

References (33)

1. Tuteja R, (2007) Malaria- an overview. Febs J 274: 4670-4679.
2. WHO (2008) The Global Malaria Action Plan: Key facts, figures, and strategies. Available: http://www.rollbackmalaria.org/gmap/index.html. Accessed 2011 October 6.
3. Ittarat W, Pickard AL, Rattanasinganchan P, Wilairatana P, Looareesuwan S, et al. (2003) Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 68: 147-152.
4. Klayman DL, (1985) Qinghaosu (artemisinin): an antimalarial drug from China. Science 228: 1049-1055.
5. Hien TT, White NJ, (1993) Qinghaosu. Lancet 341: 603-608.
6. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
7. White NJ, Olliaro P, (1998) Artemisinin and derivatives in the treatment of uncomplicated malaria. Med Trop (Mars) 58: 54-56.
8. Menard D, Matsika-Claquin MD, Djalle D, Yapou F, Manirakiza A, et al. (2005) Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of Plasmodium falciparum. Am J Trop Med Hyg 73: 616-621.
9. Breman JG, Alilio MS, Mills A, (2004) Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 1-15.
10. Rogers WO, Sem R, Tero T, Chim P, Lim P, et al. (2009) Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8: 10.
11. Nakazawa S, Kanbara H, Aikawa M, (1995) Plasmodium falciparum: recrudescence of parasites in culture. Exp Parasitol 81: 556-563.
12. Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother 54: 1872-1877.
13. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, et al. (2010) Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 202: 1362-1368.
14. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramaodoss R, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12: 391.
15. Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML, Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar J 10: 56.
16. Caillard V, Beaute-Lafitte A, Chabaud AG, Landau I, (1992) Plasmodium vinckei petteri: identification of the stages sensitive to arteether. Exp Parasitol 75: 449-456.
17. Caillard V, Beaute-Lafitte A, Chabaud A, Ginsburg H, Landau I, (1995) Stage sensitivity of Plasmodium vinckei petteri to quinine, mefloquine, and pyrimethamine. J Parasitol 81: 295-301.
18. Wasserman GM, Kumar S, Ahlers J, Ramsdell F, Berzofsky JA, et al. (1993) An approach to development of specific T-lymphocyte lines by use of preprocessed antigens in Plasmodium vinckei vinckei murine malaria. Infect Immun 61: 1958-1963.
19. Buffet PA, Milon G, Brousse V, Correas JM, Dousset B, et al. (2006) Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 107: 3745-3752.
20. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117: 381-392.
21. Kyle DE, Teja-Isavadharm P, Li Q, Leo K, (1998) Pharmacokinetics and pharmacodynamics of qinghaosu derivatives: how do they impact on the choice of drug and the dosage regimens? Med Trop (Mars) 58: 38-44.
22. Voza T, Vigario AM, Belnoue E, Gruner AC, Deschemin JC, et al. (2005) Species-specific inhibition of cerebral malaria in mice coinfected with Plasmodium spp. Infect Immun 73: 4777-4786.
23. Stevenson MM, Riley EM, (2004) Innate immunity to malaria. Nat Rev Immunol 4: 169-180.
24. Perlmann H, Kumar S, Vinetz JM, Kullberg M, Miller LH, et al. (1995) Cellular mechanisms in the immune response to malaria in Plasmodium vinckei-infected mice. Infect Immun 63: 3987-3993.
25. Xie LH, Li Q, Lin AJ, Smith K, Zhang J, et al. (2006) New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria. Antimicrob Agents Chemother 50: 1649-1655.
26. Bethell D, Se Y, Lon C, Tyner S, Saunders D, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One 6: e19283.
27. Groom AC, Schmidt EE, MacDonald IC, (1991) Microcirculatory pathways and blood flow in spleen: new insights from washout kinetics, corrosion casts, and quantitative intravital videomicroscopy. Scanning Microsc 5: 159-173; discussion 173-154.
28. Newton PN, Chotivanich K, Chierakul W, Ruangveerayuth R, Teerapong P, et al. (2001) A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and-negative erythrocytes. Blood 98: 450-457.
29. Boone KE, Watters DA, (1995) The incidence of malaria after splenectomy in Papua New Guinea. Bmj 311: 1273.
30. Saint-Yves IF, (1977) Splenectomy: follow-up of patients in the Solomon Islands. P N G Med J 20: 33-37.
31. Negreiros RM, Makimoto FH, Santana LL, Ferreira LC, Nakajima GS, et al. (2009) Experimental splenectomies and malaria in mice. Acta Cir Bras 24: 437-441.
32. Moore BR, Jago JD, Batty KT, (2008) Plasmodium berghei: parasite clearance after treatment with dihydroartemisinin in an asplenic murine malaria model. Exp Parasitol 118: 458-467.
33. Bei AK, Desimone TM, Badiane AS, Ahouidi AD, Dieye T, et al. A flow cytometry-based assay for measuring invasion of red blood cells by Plasmodium falciparum. Am J Hematol 85: 234-237.